WEBSITE BSE:544549 NSE: EARKART Inc. Year: 2021 Industry: Medical Equipment/Supplies/Accessories My Bucket: Add Stock
Last updated: 11:26
No Notes Added Yet
Earkart Limited is a HealthTech company focused on manufacturing and distributing modern hearing aids and assistive‑mobility devices. Its product lineup includes hearing aids (types like Behind‑the‑Ear, Receiver‑in‑Canal, etc.), accessories, and mobility aids like adjustable foldable walkers; it also offers multisensory educational/assistive‑device kits for the physically challenged. In addition to its own manufacturing (in a facility in Noida), Earkart trades in hearing‑aid products and parts from domestic and international brand...Read More
Earkart Limited is a HealthTech company focused on manufacturing and distributing modern hearing aids and assistive‑mobility devices. Its product lineup includes hearing aids (types like Behind‑the‑Ear, Receiver‑in‑Canal, etc.), accessories, and mobility aids like adjustable foldable walkers; it also offers multisensory educational/assistive‑device kits for the physically challenged. In addition to its own manufacturing (in a facility in Noida), Earkart trades in hearing‑aid products and parts from domestic and international brands, and services a mix of retail, clinic, government (via supply to government‑linked agencies), and franchise/clinic‑based channels. In 2025, the company launched an IPO on the SME platform raising around ₹49.26 crore, with plans to use the proceeds to expand a “Shop‑in‑Shop” (SIS) model across ENT/ophthalmic clinics nationwide, build infrastructure, and meet working‑capital needs. For the fiscal year 2025, Earkart reported revenue of approximately ₹43.19 crore and a net profit of about ₹6.88 crore — a steep growth over the prior year, reflecting improving scale and margins. ...Read Less
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹204 Cr.
Stock P/E 30.7
P/B 3.2
Current Price ₹148.3
Book Value ₹ 46.9
Face Value 10
52W High ₹266
Dividend Yield 0%
52W Low ₹ 114.5
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) |
|---|
| Net Sales |
| Other Income |
| Total Income |
| Total Expenditure |
| Operating Profit |
| Interest |
| Depreciation |
| Exceptional Income / Expenses |
| Profit Before Tax |
| Provision for Tax |
| Profit After Tax |
| Adjustments |
| Profit After Adjustments |
| Adjusted Earnings Per Share |
| #(Fig in Cr.) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|
| Net Sales | 6 | 29 | 32 | 43 | |
| Other Income | 0 | 0 | 0 | 0 | |
| Total Income | 6 | 29 | 32 | 43 | |
| Total Expenditure | 6 | 27 | 28 | 34 | |
| Operating Profit | 0 | 2 | 4 | 10 | |
| Interest | 0 | 0 | 0 | 0 | |
| Depreciation | 0 | 0 | 0 | 0 | |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | |
| Profit Before Tax | 0 | 1 | 3 | 9 | |
| Provision for Tax | 0 | 0 | 0 | 2 | |
| Profit After Tax | 0 | 1 | 3 | 7 | |
| Adjustments | 0 | 0 | 0 | 0 | |
| Profit After Adjustments | 0 | 1 | 3 | 7 | |
| Adjusted Earnings Per Share | 0.1 | 1.7 | 4.1 | 6.4 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 34% | 93% | 0% | 0% |
| Operating Profit CAGR | 150% | 0% | 0% | 0% |
| PAT CAGR | 133% | 0% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | NA% | NA% | NA% | NA% |
| ROE Average | 41% | 32% | 24% | 24% |
| ROCE Average | 44% | 32% | 25% | 25% |
| #(Fig in Cr.) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Shareholder's Funds | 5 | 7 | 13 | 20 |
| Minority's Interest | 0 | 0 | 0 | 0 |
| Borrowings | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 |
| Total Current Liabilities | 1 | 8 | 6 | 10 |
| Total Liabilities | 6 | 15 | 19 | 30 |
| Fixed Assets | 0 | 0 | 1 | 1 |
| Other Non-Current Assets | 1 | 1 | 1 | 2 |
| Total Current Assets | 4 | 14 | 17 | 27 |
| Total Assets | 6 | 15 | 19 | 30 |
| #(Fig in Cr.) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 0 | 1 | 1 |
| Cash Flow from Operating Activities | -3 | -0 | -1 | 1 |
| Cash Flow from Investing Activities | -2 | 0 | -1 | -1 |
| Cash Flow from Financing Activities | 5 | 0 | 3 | -0 |
| Net Cash Inflow / Outflow | 0 | 1 | 1 | -1 |
| Closing Cash & Cash Equivalent | 0 | 1 | 1 | 0 |
| # | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Earnings Per Share (Rs) | 0.14 | 1.74 | 4.05 | 6.36 |
| CEPS(Rs) | 0.22 | 1.94 | 4.3 | 6.78 |
| DPS(Rs) | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 6.29 | 8.65 | 17.22 | 18.86 |
| Core EBITDA Margin(%) | 2.44 | 5.65 | 11.26 | 22.26 |
| EBIT Margin(%) | 2.06 | 5.3 | 11.34 | 21.46 |
| Pre Tax Margin(%) | 1.97 | 5.02 | 10.22 | 20.44 |
| PAT Margin (%) | 1.86 | 4.54 | 9.63 | 15.41 |
| Cash Profit Margin (%) | 2.91 | 5.06 | 10.22 | 16.41 |
| ROA(%) | 1.78 | 12.72 | 18.04 | 26.86 |
| ROE(%) | 2.22 | 23.27 | 31.31 | 40.63 |
| ROCE(%) | 2.34 | 24.02 | 29.05 | 44.39 |
| Receivable days | 103.73 | 39.86 | 63.44 | 105.72 |
| Inventory Days | 47.96 | 39.38 | 67.28 | 54.05 |
| Payable days | 92.68 | 58.28 | 62.75 | 29.72 |
| PER(x) | 0 | 0 | 0 | 0 |
| Price/Book(x) | 0 | 0 | 0 | 0 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 0.04 | 0.02 | 0.08 | 0.35 |
| EV/Core EBITDA(x) | 1.38 | 0.42 | 0.71 | 1.55 |
| Net Sales Growth(%) | 0 | 408.04 | 9.82 | 35.75 |
| EBIT Growth(%) | 0 | 1206.47 | 134.73 | 156.88 |
| PAT Growth(%) | 0 | 1142.42 | 133.09 | 117.16 |
| EPS Growth(%) | 0 | 1142.1 | 133.1 | 57.06 |
| Debt/Equity(x) | 0.05 | 0.19 | 0.31 | 0.25 |
| Current Ratio(x) | 3.69 | 1.67 | 2.76 | 2.62 |
| Quick Ratio(x) | 3.04 | 0.99 | 1.75 | 1.99 |
| Interest Cover(x) | 22.58 | 18.84 | 10.1 | 21.05 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 |
| # | Sep 2025 | Mar 2026 |
|---|---|---|
| Promoter | 57.34 | 57.34 |
| FII | 5.14 | 0 |
| DII | 12.61 | 21.95 |
| Public | 24.9 | 20.71 |
| Others | 0 | 0 |
| Total | 100 | 100 |
| # | Sep 2025 | Mar 2026 |
|---|---|---|
| Promoter | 0.79 | 0.79 |
| FII | 0.07 | 0 |
| DII | 0.17 | 0.3 |
| Public | 0.34 | 0.28 |
| Others | 0 | 0 |
| Total | 1.38 | 1.38 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
ChatGPT
Claude
Perplexity
